GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » EV-to-FCF

Gensight Biologics (XPAR:SIGHT) EV-to-FCF : -1.96 (As of Apr. 30, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Gensight Biologics's Enterprise Value is €48.29 Mil. Gensight Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-24.66 Mil. Therefore, Gensight Biologics's EV-to-FCF for today is -1.96.

The historical rank and industry rank for Gensight Biologics's EV-to-FCF or its related term are showing as below:

XPAR:SIGHT' s EV-to-FCF Range Over the Past 10 Years
Min: -19.45   Med: -4.1   Max: -0.62
Current: -1.99

During the past 12 years, the highest EV-to-FCF of Gensight Biologics was -0.62. The lowest was -19.45. And the median was -4.10.

XPAR:SIGHT's EV-to-FCF is ranked worse than
100% of 391 companies
in the Biotechnology industry
Industry Median: 4.47 vs XPAR:SIGHT: -1.99

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-30), Gensight Biologics's stock price is €0.41. Gensight Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.540. Therefore, Gensight Biologics's PE Ratio for today is At Loss.


Gensight Biologics EV-to-FCF Historical Data

The historical data trend for Gensight Biologics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gensight Biologics EV-to-FCF Chart

Gensight Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.46 -17.80 -13.11 -4.63 -1.87

Gensight Biologics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.11 - -4.63 - -1.87

Competitive Comparison of Gensight Biologics's EV-to-FCF

For the Biotechnology subindustry, Gensight Biologics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gensight Biologics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gensight Biologics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Gensight Biologics's EV-to-FCF falls into.



Gensight Biologics EV-to-FCF Calculation

Gensight Biologics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=48.285/-24.663
=-1.96

Gensight Biologics's current Enterprise Value is €48.29 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Gensight Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-24.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gensight Biologics  (XPAR:SIGHT) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Gensight Biologics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.41/-0.540
=At Loss

Gensight Biologics's share price for today is €0.41.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Gensight Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.540.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Gensight Biologics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Gensight Biologics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Gensight Biologics (XPAR:SIGHT) Business Description

Traded in Other Exchanges
Address
74,rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Gensight Biologics (XPAR:SIGHT) Headlines

No Headlines